LivaNova PLC
HealthcareNASDAQ:LIVN · NASDAQ Global Select
-$0.55 today
Vol 0.72M · Avg 0.79M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-20.2%
avg -8.1%
ROIC
10.9%
avg -1.1%
ROA
-9.3%
avg -4.2%
Analysis
ROIC is currently the strongest return metric at 10.9% versus its period average of -1.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Vladimir A. Makatsaria | Chief Executive Officer & Director | $2.37M | — | 53 | $52,227.00 | 0.10% |
Franco Poletti | President of Cardiopulmonary Business Unit | $1.13M | — | — | $12,125.00 | 0.02% |
Alex Shvartsburg | Chief Financial Officer | $1.12M | — | 56 | $57,515.00 | 0.10% |
Natalia Kozmina | Chief Human Resources Officer | $1.09M | — | 54 | $9,792.00 | 0.02% |
Ahmet Tezel | Chief Innovation Officer | $1.07M | — | 51 | $5,343.00 | <0.01% |
Deanna Wilke | Vice President of Corporate Communications | — | — | — | — | — |
John Webb | Vice President of Sleep Apnea and Epilepsy | — | — | — | $29,676.00 | 0.05% |
Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | — | — | 70 | — | — |
Philip Kowalczyk | Chief Strategy & Corporate Development Officer | — | — | — | — | — |
Sujay Mashru | Senior Vice President of APAC & Growth Markets | — | — | — | — | — |
Lindsey Little | VP & Chief Accounting Officer | — | — | — | — | — |
Lucile Blaise | Global Head of Commercialization - Obstructive Sleep Apnea (OSA) | — | — | 55 | — | — |
Stephanie Bolton | President of Global Epilepsy | — | — | 44 | $30,566.00 | 0.06% |
Briana Gotlin | Vice President of Investor Relations | — | — | — | — | — |
Sarah Mohr | Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$234,585.00
Net Sentiment
$234,585.00
Net selling
Most Active
Bianchi Francesco
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $234,585.00 over the last 12 months. That adds up to net selling of $234,585.00. Bianchi Francesco was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +19.6% | +9.9% (15yr)2 analysts |
| Revenue | N/A | N/A | +10.1% | +14.9% (15yr)6 analysts |
| Net Income | N/A | N/A | +17.0% | +15.3% (15yr)6 analysts |
| EBIT | N/A | N/A | +13.3% | N/A6 analysts |
Analysis
Recent growth has been strongest in EPS at +19.6% over three years. Forward estimates point to Net Income at +15.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Heartflow, Inc. Common Stock
NASDAQ:HTFL
$2.87B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Prestige Consumer Healthcare Inc.
NYSE:PBH
$2.26B
Surgery Partners, Inc.
NASDAQ:SGRY
$2.00B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Alphatec Holdings, Inc.
NASDAQ:ATEC
$1.27B
Who manages LIVN?
LivaNova PLC (LIVN) lists 15 active executives. The top listed executive is Ahmet Tezel, Chief Innovation Officer.
Are LIVN insiders buying or selling?
Recent insider activity shows net buying of $3.71M.
Explore More
Continue the stock analysis
Jump to another research area for this company.